InsiderTradr

Evotec SE (0IRF.IL)

IOB · EUR · Healthcare · Drug Manufacturers - Specialty & Generic

€2.86 (+0.95%) as of

Key statistics

Market cap
555.35M
EPS (TTM)
-0.5800
52-week range
0.0000 – 7.2140
Beta
1.08
Revenue (TTM)
798.41M
Profit margin
-12.94%

About Evotec SE

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Headquarters
Hamburg, Germany
Employees
5,067

evotec.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks